Tailoring therapy for heart failure: the pharmacogenomics of adrenergic receptor signaling

References

• RengoFLeoscoDIacovoniAEpidemiology and risk factors for heart failure in the elderlyItal Heart J20045Suppl 109S16S Italian15712508
   PubMedGoogle Scholar
• YancyCWJessupMBozkurtBWriting Committee MembersAmerican College of Cardiology Foundation/American Heart Association Task force on Practice Guidelines2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelinesCirculation201312816e240e32723741058
   PubMed Web of Science ®Google Scholar
• BahramiHKronmalRBluemkeDADifferences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosisArch Intern Med2008168192138214518955644
   PubMed Web of Science ®Google Scholar
• LymperopoulosARengoGKochWJAdrenal adrenoceptors in heart failure: fine-tuning cardiac stimulationTrends Mol Med2007131250351117981507
   PubMed Web of Science ®Google Scholar
• LymperopoulosARengoGKochWJAdrenergic nervous system in heart failure: pathophysiology and therapyCirc Res2013113673975323989716
   PubMed Web of Science ®Google Scholar
• AzumaJNonenSChronic heart failure: beta-blockers and pharmacogeneticsEur J Clin Pharmacol200965131718839161
   PubMed Web of Science ®Google Scholar
• CIBIS II Investigators and CommitteesThe Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialLancet199935391310023943
   PubMed Web of Science ®Google Scholar
• MERIT-HF Study GroupEffect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)Lancet19993532001200910376614
   PubMed Web of Science ®Google Scholar
• PackerMCoatsAJFowlerMBEffect of carvedilol on survival in severe chronic heart failureN Engl J Med20013441651165811386263
   PubMed Web of Science ®Google Scholar
• FlegJLPiñaILBaladyGJAssessment of functional capacity in clinical and research applications: An advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart AssociationCirculation2000102131591159711004153
   PubMed Web of Science ®Google Scholar
• ShinJJohnsonJABeta-blocker pharmacogenetics in heart failureHeart Fail Rev201015318719618437562
   PubMed Web of Science ®Google Scholar
• JohnsonJALiggettSBCardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directionsClin Pharmacol Ther201189336637821289619
   PubMed Web of Science ®Google Scholar
• RengoGLymperopoulosAKochWJFuture g protein-coupled receptor targets for treatment of heart failureCurr Treat Options Cardiovasc Med200911432833819627665
   PubMedGoogle Scholar
• RengoGLymperopoulosALeoscoDKochWJGRK2 as a novel gene therapy target in heart failureJ Mol Cell Cardiol201150578579220800067
   PubMed Web of Science ®Google Scholar
• LeoscoDRengoGIaccarinoGExercise training and beta-blocker treatment ameliorate age-dependent impairment of beta-adrenergic receptor signaling and enhance cardiac responsiveness to adrenergic stimulationAm J Physiol Heart Circ Physiol20072933H1596H160317557919
   PubMed Web of Science ®Google Scholar
• CiccarelliMChuprunJKRengoGG protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemiaCirculation2011123181953196221518983
   PubMed Web of Science ®Google Scholar
• RengoGPerrone-FilardiPFemminellaGDTargeting the β-adrenergic receptor system through G-protein-coupled receptor kinase 2: a new paradigm for therapy and prognostic evaluation in heart failure: from bench to bedsideCirc Heart Fail20125338539122589366
   PubMed Web of Science ®Google Scholar
• LymperopoulosARengoGKochWJGRK2 inhibition in heart failure: something old, something newCurr Pharm Des201218218619122229578
   PubMed Web of Science ®Google Scholar
• PetrofskiJAKochWJThe beta-adrenergic receptor kinase in heart failureJ Mol Cell Cardiol2003351167117414519424
   PubMed Web of Science ®Google Scholar
• RengoGZincarelliCFemminellaGDMyocardial β(2) -adrenoceptor gene delivery promotes coordinated cardiac adaptive remodelling and angiogenesis in heart failureBr J Pharmacol201216682348236122452704
   PubMed Web of Science ®Google Scholar
• BarreseVTaglialatelaMNew advances in beta-blocker therapy in heart failureFront Physiol2013432324294204
   PubMed Web of Science ®Google Scholar
• RengoGGalassoGFemminellaGDReduction of lymphocyte G protein-coupled receptor kinase-2 (GRK2) after exercise training predicts survival in patients with heart failureEur J Prev Cardiol201421141123689525
   PubMed Web of Science ®Google Scholar
• RengoGLeoscoDZincarelliCAdrenal GRK2 lowering is an underlying mechanism for the beneficial sympathetic effects of exercise training in heart failureAm J Physiol Heart Circ Physiol20102986H2032H203820304818
   PubMed Web of Science ®Google Scholar
• RaakePWVingeLEGaoEG protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failureCirc Res2008103441342218635825
   PubMed Web of Science ®Google Scholar
• LymperopoulosARengoGZincarelliCKimJKochWJAdrenal beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levelsJ Am Coll Cardiol201157335636521232674
   PubMed Web of Science ®Google Scholar
• LymperopoulosARengoGZincarelliCKimJSoltysSKochWJAn adrenal beta-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivoProc Natl Acad Sci U S A2009106145825583019289825
   PubMed Web of Science ®Google Scholar
• LymperopoulosARengoGZincarelliCSoltysSKochWJModulation of adrenal catecholamine secretion by in vivo gene transfer and manipulation of G protein-coupled receptor kinase-2 activityMol Ther200816230230718223549
   PubMed Web of Science ®Google Scholar
• LymperopoulosARengoGFunakoshiHEckhartADKochWJAdrenal GRK2 upregulation mediates sympathetic overdrive in heart failureNat Med200713331532317322894
   PubMed Web of Science ®Google Scholar
• LymperopoulosARengoGGaoEEbertSNDornGW2ndKochWJReduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarctionJ Biol Chem201028521163781638620351116
   PubMed Web of Science ®Google Scholar
• RengoGLymperopoulosAZincarelliCMyocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failureCirculation20091191899819103992
   PubMed Web of Science ®Google Scholar
• RockmanHAChienKRChoiDJExpression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted miceProc Natl Acad Sci U S A19989512700070059618528
   PubMed Web of Science ®Google Scholar
• RengoGLymperopoulosAZincarelliCBlockade of β-adrenoceptors restores the GRK2-mediated adrenal α(2)-adrenoceptor-catecholamine production axis in heart failureBr J Pharmacol201216682430244022519418
   PubMed Web of Science ®Google Scholar
• RengoGCannavoALiccardoDVascular endothelial growth factor blockade prevents the beneficial effects of β-blocker therapy on cardiac function, angiogenesis and remodeling in heart failureCirc Heart Fail2013661259126724029661
   PubMed Web of Science ®Google Scholar
• von HomeyerPSchwinnDAPharmacogenomics of β-adrenergic receptor physiology and response to beta-blockadeAnesth Analg201111361305131821965354
   PubMed Web of Science ®Google Scholar
• RathzDABrownKMKramerLALiggettSBAmino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted traffickingJ Cardiovasc Pharmacol200239215516011791000
   PubMed Web of Science ®Google Scholar
• LevinMCMarulloSMuntanerOAnderssonBMagnussonYThe myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulationJ Biol Chem200227734304293043512034720
   PubMed Web of Science ®Google Scholar
• MasonDAMooreJDGreenSALiggettSBA gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptorJ Biol Chem199927418126701267410212248
   PubMed Web of Science ®Google Scholar
• RathzDAGregoryKNFangYBrownKMLiggettSBHierarchy of polymorphic variation and desensitization permutations relative to beta 1- and beta 2-adrenergic receptor signalingJ Biol Chem200327812107841078912525504
   PubMed Web of Science ®Google Scholar
• Mialet PerezJRathzDAPetrashevskayaNNBeta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failureNat Med20039101300130514502278
   PubMed Web of Science ®Google Scholar
• LiggettSBMialet-PerezJThaneemit-ChenSA polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failureProc Natl Acad Sci U S A200610330112881129316844790
   PubMed Web of Science ®Google Scholar
• SmallKMForbesSLRahmanFFBridgesKMLiggettSBA four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectorsJ Biol Chem200027530230592306410801795
   PubMed Web of Science ®Google Scholar
• TalamehJALanfearDEPharmacogenetics in chronic heart failure: new developments and current challengesCurr Heart Fail Rep201291233222135185
   PubMedGoogle Scholar
• SmallKMMcGrawDWLiggettSBPharmacology and physiology of human adrenergic receptor polymorphismsAnnu Rev Pharmacol Toxicol20034338141112540746
   PubMed Web of Science ®Google Scholar
• GreenSATurkiJInnisMLiggettSBAmino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory propertiesBiochemistry19943332941494197915137
   PubMed Web of Science ®Google Scholar
• PanebraAWangWCMaloneMMCommon ADRB2 haplotypes derived from 26 polymorphic sites direct beta2-adrenergic receptor expression and regulation phenotypesPloS One201057e1181920686604
   PubMed Web of Science ®Google Scholar
• LiggettSBCresciSKellyRJA GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failureNat Med200814551051718425130
   PubMed Web of Science ®Google Scholar
• LobmeyerMTWangLZinehIPolymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patientsPharmacogenet Genomics2011211424921127457
   PubMed Web of Science ®Google Scholar
• ChanSWHuMTomlinsonBThe pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failureExpert Opin Drug Metab Toxicol20128776779022621216
   PubMed Web of Science ®Google Scholar
• TerraSGHamiltonKKPaulyDFBeta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapyPharmacogenet Genomics200515422723415864115
   PubMedGoogle Scholar
• de GrootePHelbecqueNLamblinNAssociation between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failurePharmacogenet Genomics200515313714215861037
   PubMed Web of Science ®Google Scholar
• Beta-Blocker Evaluation of Survival Trial InvestigatorsA trial of the beta-blocker bucindolol in patients with advanced chronic heart failureN Engl J Med2001344221659166711386264
   PubMed Web of Science ®Google Scholar
• KurnikDLiCSofoworaGGBeta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockadePharmacogene Genomics20081810895902
   Web of Science ®Google Scholar
• FiuzatMNeelyMLStarrAZAssociation between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTION DNA substudyEur J Heart Fail201315325826623115322
   PubMed Web of Science ®Google Scholar
• BaudhuinLMMillerWLTrainLRelation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failureAm J Cardiol2010106340240820643254
   PubMed Web of Science ®Google Scholar
• ShinJLobmeyerMTGongYRelation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failureAm J Cardiol200799225025517223428
   PubMed Web of Science ®Google Scholar
• LanfearDEJonesPGMarshSCresciSMcLeodHLSpertusJABeta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndromeJAMA2005294121526153316189366
   PubMed Web of Science ®Google Scholar